Singapore Medical Group reviewing current and future acquisitions strategies

CATALIST-LISTED Singapore Medical Group (SMG) said that it is undertaking a review of its current and future acquisitions strategies, it said in a filing with the Singapore Exchange (SGX) on Monday evening.

Without identifying what specifically prompted this filing, the group said that in the recent course of work, through dialogues with the professional governing body and professional doctors, its management's attention has been drawn to the Singapore Medical Council's ethical code and ethical guidelines (ECEG).

In particular, SMG highlighted that the ECEG states that doctors must always place patients' best interests above their personal interests and any business or financial considerations.

The group added that it would make further announcements as and when there are material updates or developments.

"Each case will be judged by its particular facts and circumstances," the group said.